BiotechTube

MK-3222 200 mg + MK-3222 100 mg + Placebo to MK-3222 + Placebo to Etanercept + Etanercept 50 mg

Phase 3Withdrawn
0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Plaque-type Psoriasis

Conditions

Plaque-type Psoriasis

Trial Timeline

Sep 1, 2013 → Aug 1, 2018

NCT ID
NCT01936688

About MK-3222 200 mg + MK-3222 100 mg + Placebo to MK-3222 + Placebo to Etanercept + Etanercept 50 mg

MK-3222 200 mg + MK-3222 100 mg + Placebo to MK-3222 + Placebo to Etanercept + Etanercept 50 mg is a phase 3 stage product being developed by Sun Pharmaceutical for Plaque-type Psoriasis. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT01936688. Target conditions include Plaque-type Psoriasis.

What happened to similar drugs?

1 of 12 similar drugs in Plaque-type Psoriasis were approved

Approved (1) Terminated (0) Active (11)
✅Olux-E Foam + Clobex lotionGSK plcApproved
🔄AIN457 150 mg + AIN457 300 mg + PlaceboNovartisPhase 3
🔄secukinumab 150 mgNovartisPhase 3
🔄Experimental : Secukinumab low dose + Experimental: Secukinumab high dose + Placebo Comparator: Secukinumab Placebo + Active Comparator: EtanerceptNovartisPhase 3
🔄Placebo + Secukinumab 150mg + Secukinumab 300mgNovartisPhase 3
🔄SecukinumabNovartisPhase 3
🔄Secukinumab (AIN457) + PlaceboNovartisPhase 3

Hype Score Breakdown

Clinical
17
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01936688Phase 3Withdrawn

Competing Products

18 competing products in Plaque-type Psoriasis

See all competitors
ProductCompanyStageHype Score
AIN457 150 mg + AIN457 300 mg + PlaceboNovartisPhase 3
40
AIN457 + AIN457A + AIN457A + PlaceboNovartisPhase 2
35
secukinumab + placeboNovartisPhase 2
35
secukinumab 150 mgNovartisPhase 3
40
Experimental : Secukinumab low dose + Experimental: Secukinumab high dose + Placebo Comparator: Secukinumab Placebo + Active Comparator: EtanerceptNovartisPhase 3
40
Placebo + Secukinumab 150mg + Secukinumab 300mgNovartisPhase 3
40
SecukinumabNovartisPhase 3
40
AIN457 + PlaceboNovartisPhase 2
35
Secukinumab (AIN457) + PlaceboNovartisPhase 3
40
secukinumab 150 mg + placebo to secukinumab 150 mgNovartisPhase 3
40
secukinumab low dose + secukinumab high doseNovartisPhase 3
40
AIN457 150mg + AIN457 300mgNovartisPhase 3
40
secukinumab 150mg + secukinumab 10mg/kg i.v. regimenNovartisPhase 3
40
CJM112 + SecukinumabNovartisPhase 1
29
secukinumab 150 mg + secukinumab 300 mg + placeboNovartisPhase 3
40
AIN457 + PlaceboNovartisPhase 2
35
AN2728 Ointment + AN2728 VehiclePfizerPhase 1
29
Olux-E Foam + Clobex lotionGSK plcApproved
43